CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma
Shintaro Iwata(National Cancer Centre Japan), Miki Ohira(Saitama Cancer Center)
Cited by 25
Related Papers
Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
|Clinical Cancer Research|2014|99
Circulating MicroRNA-92b-3p as a Novel Biomarker for Monitoring of Synovial Sarcoma
|Scientific Reports|2017|62
Japanese Orthopaedic Association (JOA) clinical practice guidelines on the management of soft tissue tumors 2020 - Secondary publication
|Journal of Orthopaedic Science|2022|34